VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 404 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2016. The put-call ratio across all filers is 0.94 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2015 | $825,170,000 | +15.3% | 8,117,753 | +102.3% | 25.22% | +78.3% |
| Q3 2015 | $715,937,000 | +5.5% | 4,013,551 | +31.4% | 14.14% | +19.9% |
| Q2 2015 | $678,724,000 | +30.3% | 3,055,251 | +16.5% | 11.79% | +5.7% |
| Q1 2015 | $521,033,000 | -1.4% | 2,623,268 | -29.0% | 11.16% | -25.9% |
| Q4 2014 | $528,686,000 | -9.6% | 3,694,263 | -17.1% | 15.06% | +17.4% |
| Q3 2014 | $584,778,000 | +18.8% | 4,457,153 | +14.2% | 12.82% | -5.9% |
| Q2 2014 | $492,231,000 | +28.2% | 3,902,877 | +34.0% | 13.63% | +10.7% |
| Q1 2014 | $384,028,000 | -4.6% | 2,913,051 | -15.0% | 12.32% | -7.2% |
| Q4 2013 | $402,455,000 | +6.2% | 3,428,063 | -5.6% | 13.27% | +39.2% |
| Q3 2013 | $378,960,000 | +14.3% | 3,632,322 | -5.7% | 9.54% | -26.9% |
| Q2 2013 | $331,435,000 | – | 3,850,317 | – | 13.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |